PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Innovative Therapies to Drive the Opioid and Non-Opioid Pain Management Pharmaceuticals Markets - New analysis from Frost & Sullivan, U.S. Opioid and Non-Opioid Pain Management Pharmaceuticals Markets, reveals that the market earned revenues of $5.90 billion in 2006 and estimates this to reach $10.17 billion in 2013
Innovative Therapies to Drive the Opioid and Non-Opioid Pain Management Pharmaceuticals Markets

 

NewswireToday - /newswire/ - Palo Alto, CA, United States, 2007/04/17 - New analysis from Frost & Sullivan, U.S. Opioid and Non-Opioid Pain Management Pharmaceuticals Markets, reveals that the market earned revenues of $5.90 billion in 2006 and estimates this to reach $10.17 billion in 2013.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

A rapidly ageing population is driving the need for effective pain management therapies for acute and chronic pain. Since there is considerable unmet medical need in the treatment of pain, newer and more effective therapies will be welcome in the opioid and non-opioid pain management pharmaceuticals market.

New analysis from Frost & Sullivan (pharmaceuticals.frost.com), U.S. Opioid and Non-Opioid Pain Management Pharmaceuticals Markets, reveals that the market earned revenues of $5.90 billion in 2006 and estimates this to reach $10.17 billion in 2013.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants an overview of the latest analysis of the U.S. Opioid and Non-Opioid Pain Management Pharmaceuticals Markets, then send an email to Melina Trevino - Corporate Communications at melina.trevino[.]frost.com with the following information: your full name, company name, title, telephone number, email address, city, state, and country. We will send you the information via email upon receipt of the above information.

The significant recall of Vioxx and Bextra from the market, coupled with the robust demand for pain management therapies, is creating substantial opportunities for novel therapies in the opioid and non-opioid pain management markets. However, there have been no blockbuster drugs to fill the gap created by their exit and non-opioid therapies have extensively available generics.

Despite the lack of major breakthrough therapies, specialty pharma and drug delivery companies have successfully engaged in lifecycle management partnerships to relaunch older therapies in newer formulations.

“Noting the remarkable market potential, several “Big Pharma”, specialty pharmaceutical, and drug delivery companies have been planning for market expansion, thereby driving market growth,” says Frost & Sullivan Research Analyst Barath Shankar S.

To sustain this growth momentum, market participants must pay attention to the increasing apprehensions regarding the safety profile of opioid and non-opioid therapies. The escalating regulatory and media scrutiny on opioid therapies have compelled drug companies to address the issue of potential drug abuse.

“The collaborations between pharmaceuticals and drug delivery companies have ensured that next-generation drugs have abuse- and tamper-resistant formulations,” notes Shankar. “Market participants can promote this benefit to not only expand their customer base but also meet the increasingly stringent regulatory norms.”

The U.S. Opioid and Non-Opioid Pain Management Pharmaceuticals Markets is part of the Pharmaceutical and Biotechnology Growth Partnership Service, which also includes research in the following markets: U.S. pulmonary arterial hypertension markets, analysis of top 10 specialty pharmaceutical companies, and U.S. drug discovery contract research organization markets. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership service, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective, and combines ongoing analysis of markets, technologies, econometrics, and demographics.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Innovative Therapies to Drive the Opioid and Non-Opioid Pain Management Pharmaceuticals Markets

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Melina Trevino 
210.247.2440 melina.trevino[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research
Persistence Market Research Publishes Biopharmaceutical Membrane Filtration Market Forecast Over 2017-2025
Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022
FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
BD to Invest $60 Million in Nebraska Manufacturing Facility
MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx
Pulse Certified As A Level Four Multichannel Content Agency by Veeva
Earthly Mist - Opioid-Alternative Painkiller, Kratom Now Available in Oklahoma City
MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  MagLar, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)